6/6/2022
PITTSBURGH – UPMC Presbyterian Shadyside and UPMC Children's Hospital of Pittsburgh have been designated as Comprehensive Radiopharmaceutical Therapy Centers of Excellence by the Society of Nuclear Medicine & Molecular Imaging (SNMMI), which recognizes facilities that offer the latest technology, cutting-edge research, Food and Drug Administration-approved radiopharmaceutical therapies and the best health care possible in this field of medicine.
“Such an honorable designation can come only to a center that has the unique combination of people, place and resources that we have here at UPMC. Some of these therapies are not available in other sites in Western Pennsylvania or even other centers across the country,” said Ashok Muthukrishnan, M.D., chief of nuclear medicine at UPMC. “This award means our patients are getting the best possible care and service right here in Pittsburgh.” The goal of the SNMMI designation is to ensure that patients have reliable access to high-quality radiopharmaceutical therapy, well-integrated into their pathway of care, delivered by highly qualified therapy teams, at technically qualified sites and led by physicians appropriately trained in nuclear medicine acting as the patient’s nuclear oncologist.
Further information on the Centers of Excellence designation and on radionucleotide therapies can be found on the Patient Information Portal on the SNMMI website.
PHOTO DETAILS: (click images for high-res versions)
CREDIT: UPMC
CAPTION: Ashok Muthukrishnan, MD
